Scholar Rock Holding (SRRK) Operating Income (2017 - 2026)
Scholar Rock Holding's quarterly Operating Income came in at -$102.0 million in Q1 2026, down 32.33% year-on-year from -$150.8 million in Q1 2025, and down 11.01% quarter-over-quarter from -$91.9 million in Q4 2025.
Scholar Rock Holding has reported Operating Income for 10 years, with the latest figure at -$102.0 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income fell 32.33% year-over-year to -$102.0 million; the trailing twelve-month figure through Mar 2026 stood at -$409.6 million (down 51.29% YoY), and the FY2025 full-year result was -$384.6 million, down 52.6% from the prior year.
- Operating Income for Q1 2026 stood at -$102.0 million, down from -$91.9 million in the prior quarter.
- The five-year high for Operating Income was -$6.9 million in Q1 2022, with the low at -$112.1 million in Q2 2025.
- Average Operating Income over 5 years is -$61.4 million, with a median of -$58.4 million recorded in 2024.
- Year-over-year, Operating Income jumped 74.52% in 2022 and sank 484.29% in 2023.
- Tracing SRRK's Operating Income over 5 years: stood at -$40.4 million in 2022, then retreated by 18.81% to -$48.0 million in 2023, then slumped by 44.4% to -$69.4 million in 2024, then slumped by 32.5% to -$91.9 million in 2025, then dropped by 11.01% to -$102.0 million in 2026.
- The last three Operating Income figures came in at -$102.0 million (Q1 2026), -$91.9 million (Q4 2025), and -$103.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | -102.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -102.02 Mn |
| Dec 31, 2025 | -91.90 Mn |
| Sep 30, 2025 | -103.55 Mn |
| Jun 30, 2025 | -112.11 Mn |
| Mar 31, 2025 | -77.09 Mn |
| Dec 31, 2024 | -69.36 Mn |
| Sep 30, 2024 | -64.78 Mn |
| Jun 30, 2024 | -59.50 Mn |
| Mar 31, 2024 | -58.42 Mn |
| Dec 31, 2023 | -48.03 Mn |
| Sep 30, 2023 | -43.67 Mn |
| Jun 30, 2023 | -39.08 Mn |
| Mar 31, 2023 | -40.51 Mn |
| Dec 31, 2022 | -40.43 Mn |
| Sep 30, 2022 | -43.86 Mn |
| Jun 30, 2022 | -43.15 Mn |
| Mar 31, 2022 | -6.93 Mn |
| Dec 31, 2021 | -35.36 Mn |
| Sep 30, 2021 | -37.08 Mn |
| Jun 30, 2021 | -30.27 Mn |
| Mar 31, 2021 | -27.21 Mn |
| Dec 31, 2020 | -26.10 Mn |
| Sep 30, 2020 | -23.62 Mn |
| Jun 30, 2020 | -19.46 Mn |
| Mar 31, 2020 | -17.69 Mn |
| Dec 31, 2019 | -12.35 Mn |
| Sep 30, 2019 | -17.11 Mn |
| Jun 30, 2019 | -13.39 Mn |
| Mar 31, 2019 | -11.70 Mn |
| Dec 31, 2018 | -15.56 Mn |
| Sep 30, 2018 | -11.23 Mn |
| Jun 30, 2018 | -14.88 Mn |
| Mar 31, 2018 | -9.02 Mn |
| Dec 31, 2017 | -8.46 Mn |
| Sep 30, 2017 | -5.94 Mn |
| Jun 30, 2017 | -5.89 Mn |